PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer

PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer

Saved in:

Bibliographic Details
Main Authors:	Abul Azad, Maryam Arshad, Daniele Generali, Katharina Feldinger, Merel Gijsen, Carla Strina, Mariarosa Cappelletti, Daniele Andreis, Russell Leek, Syed Haider, Pirkko‐Liisa Kellokumpu‐Lehtinen, Ioannis Roxanis, Adrian Llewellyn Harris, Abeer Mahmoud Shaaban, Heikki Joensuu, Anthony Kong
Format:	Article
Language:	English
Published:	Wiley 2025-01-01
Series:	Cancer Communications
Online Access:	https://doi.org/10.1002/cac2.12632
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
by: Sietske B.M. Gaykema, et al.
Published: (2014-07-01)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
by: Satomi Watanabe, et al.
Published: (2019-03-01)

Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma
by: Muhammad Shahid Iqbal, et al.
Published: (2014-01-01)

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
by: Andrea L. A. Wong, et al.
Published: (2012-01-01)

Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany
by: Kirsten Merx, et al.
Published: (2016-01-01)

Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient
by: Nu T. Lu, et al.
Published: (2015-09-01)

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
by: Sara M Tolaney, et al.
Published: (2022-10-01)

Investigation of <i>ITGB3</i> Heterogeneity to Overcome Trastuzumab Resistance in HER2-Positive Breast Cancer
by: Asiye Busra Boz Er
Published: (2024-12-01)

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre
by: Anna-Maria Lazaratos, et al.
Published: (2024-12-01)

Deep learning-based prediction of HER2 status and trastuzumab treatment efficacy of gastric adenocarcinoma based on morphological features
by: Zhida Wu, et al.
Published: (2025-01-01)

HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
by: Salvatore Siena, et al.
Published: (2024-11-01)

A versatile gold leaf immunosensor with a novel surface functionalization strategy based on protein L and trastuzumab for HER2 detection
by: Ivana Kundacina, et al.
Published: (2025-01-01)

Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
by: Salvatore Siena, et al.
Published: (2025-01-01)

A Case of Trastuzumab-Associated Cardiomyopathy Presenting as an Acute Coronary Syndrome: Acute Trastuzumab Cardiotoxicity
by: Sylvana Hidalgo, et al.
Published: (2013-01-01)

Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan
by: Ünal Metin Tokat, et al.
Published: (2025-01-01)

Response to trastuzumab deruxtecan and delayed immune-related events in a patient with metastatic HER2-positive NSCLC: a case report and literature review
by: Lu Wang, et al.
Published: (2025-01-01)

Quercetin inhibits truncated isoform of dopamine- and cAMP-regulated phosphoprotein as adjuvant treatment for trastuzumab therapy resistance in HER2-positive breast cancer
by: Han-Sheng Chang, et al.
Published: (2024-09-01)

Diffuse Spontaneous Laryngeal Hemorrhage with Trastuzumab
by: Lauren Klute, et al.
Published: (2020-01-01)

Trastuzumab Resistance: Role for Notch Signaling
by: Kinnari Mehta, et al.
Published: (2009-01-01)

Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab to chemotherapy plus trastuzumab as neoadjuvant therapy
by: Huanhuan Li, et al.
Published: (2025-02-01)

Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): efficacy, safety and biomarker analysis of a prospective, multicentre, response-adapted study
by: Fei Wang, et al.
Published: (2025-01-01)

PTPN2 Downregulation Is Associated with Albuminuria and Vitamin D Receptor Deficiency in Type 2 Diabetes Mellitus
by: Li Zheng, et al.
Published: (2018-01-01)

Case report: JAK inhibitor treatment of immune dysregulation symptoms in a patient with PTPN2 deficiency
by: Anna Roppelt, et al.
Published: (2025-01-01)

ESTIMASI HASIL PRODUKSI TBS DI PTPN IV REGIONAL 4 DENGAN METODE INTERPOLASI POLINOM
by: PUSPA HANAYA LATIFAH ERJANDSA, et al.
Published: (2024-11-01)

The Genetics of PTPN1 and Obesity: Insights from Mouse Models of Tissue-Specific PTP1B Deficiency
by: Ryan C. Tsou, et al.
Published: (2012-01-01)

Association of PTPN22 Haplotypes (−1123G>C/+1858C>T) with Rheumatoid Arthritis in Western Mexican Population
by: Yeniley Ruiz-Noa, et al.
Published: (2017-01-01)

Arterial Stiffness in Breast Cancer Patients Treated with Anthracycline and Trastuzumab-Based Regimens
by: Özlem Yersal, et al.
Published: (2018-01-01)

Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer
by: Jonathan Henricks, et al.
Published: (2025-02-01)

The Effect of Work Life Balance and Perceived Organizational Support on Work Engagement in Female Employees of PTPN I Regional 4 Surabaya
by: Della Widya Pramudita, et al.
Published: (2025-01-01)

Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus
by: Emad Dawoud, et al.
Published: (2025-01-01)

Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan
by: Alessandra Fabi, et al.
Published: (2025-01-01)

In Her Words:
by: Oriana Quaglietta Bernal
Published: (2022-02-01)

‘Her Room Was Her World’: Nellie Sloggett and North Cornish Folklore
by: Simon Young
Published: (2017-12-01)

Her mistletoe miracle
by: FOx Roz Denny
Published: (2008)

Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma
by: Laura Scalambra, et al.
Published: (2025-01-01)

Intrathecal Trastuzumab Treatment of the Neoplastic Meningitis due to Breast Cancer: A Case Report and Review of the Literature
by: Cristina Dumitrescu, et al.
Published: (2013-01-01)

A Cost-Effective and Robust Cell-Based Bioassay Method for Evaluating the Bioactivity of Trastuzumab-like Antibodies
by: Pooja Bharali, et al.
Published: (2024-12-01)

Tumoral Prostate Shows Different Expression Pattern of Somatostatin Receptor 2 (SSTR2) and Phosphotyrosine Phosphatase SHP-1 (PTPN6) According to Tumor Progression
by: Ariel Ernesto Cariaga-Martinez, et al.
Published: (2009-01-01)

Prognosis and cardiotoxicity associated to adjuvant trastuzumab for breast cancer: real world study in a public health system
by: Ana Elisa Ribeiro da Silva Cabello, et al.
Published: (2025-01-01)

PROTAGORAS: HER ŞEYİN ÖLÇÜSÜ İNSAN
by: Lokman Çilingir
Published: (2022-12-01)